SS-31 (Elamipretide)

SS-31, also known as Elamipretide and formerly designated Bendavia and MTP-131, is a synthetic cell-permeable tetrapeptide with the sequence D-Arg-2',6'-dimethyltyrosine(Dmt)-Lys-Phe-NH2 and a molecular weight of approximately 640 Da. The alternating aromatic-cationic motif (positive charge, aromatic ring, positive charge, aromatic ring) enables selective partitioning into the inner mitochondrial membrane (IMM), where it accumulates at concentrations approximately 1,000-fold higher than in the cytoplasm within minutes of cellular exposure.

The primary molecular target of SS-31 is cardiolipin, a unique diphosphatidylglycerol lipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin constitutes approximately 20% of IMM lipid content and plays an essential structural role in organizing electron transport chain (ETC) supercomplexes. It directly interacts with complexes I, III, IV, and the ATP synthase (complex V), anchoring them in the optimal configuration for efficient electron transfer. SS-31 binds to cardiolipin through electrostatic interactions between its cationic residues and cardiolipin's anionic phosphate groups, stabilizing its lamellar structure and preventing the peroxidation-driven phase transitions that occur with aging.

The downstream functional consequences of cardiolipin stabilization are measurable and significant. In aged mitochondria, SS-31 restores proper ETC supercomplex assembly, reducing electron leakage at complexes I and III. This decreases mitochondrial reactive oxygen species (ROS) production by 40-60% while simultaneously increasing ATP synthesis by 30-50%. These effects were demonstrated within 1 hour of treatment in the study by Siegel et al. published in Aging Cell (2013, DOI: 10.1111/acel.12102), which showed that SS-31 rapidly reversed age-related mitochondrial dysfunction in cardiac tissue from old mice, restoring mitochondrial function to near-youthful levels.

SS-31 has been evaluated in multiple clinical trials under the name Elamipretide. In a Phase 2 trial for Barth syndrome, a rare X-linked genetic disorder caused by mutations in the tafazzin gene that impair cardiolipin remodeling, SS-31 improved the 6-minute walk test distance and cardiac stroke volume. Phase 2 trials in heart failure with preserved ejection fraction (HFpEF) showed improvements in left ventricular volumes. Trials in primary mitochondrial myopathy and age-related macular degeneration (dry AMD) have also been conducted. The TAZPOWER trial and MMPOWER-3 trial represent the most advanced clinical programs.

Pharmackinetically, SS-31 is rapidly absorbed after subcutaneous injection with a Tmax of approximately 30 minutes. The plasma elimination half-life is approximately 3-4 hours in humans. However, the functional mitochondrial effects persist well beyond plasma clearance, as SS-31 remains bound to cardiolipin in the IMM with a tissue residence time substantially longer than its plasma half-life. The peptide is renally cleared without significant hepatic metabolism, and no active metabolites have been identified. Bioavailability after subcutaneous injection is approximately 75-85%.

In aged mouse models, Siegel et al. (Aging Cell 2013) demonstrated that 8 weeks of SS-31 treatment reversed established cardiac hypertrophy, improved diastolic function, reduced mitochondrial ROS, and increased exercise endurance on treadmill testing. These improvements occurred in mice aged 24-28 months, equivalent to approximately 70-80 human years. Cardiomyocyte mitochondria showed restored cristae density and reduced lipid peroxidation on electron microscopy.

For reconstitution and storage, lyophilized SS-31 should be reconstituted with sterile water or bacteriostatic water. The reconstituted solution should be stored at 2-8 degrees C and used within 30 days. Lyophilized powder is stable at -20 degrees C for extended periods. SS-31 is highly water-soluble due to its cationic nature and does not require organic co-solvents for dissolution. Solutions should be protected from prolonged light exposure.

The safety profile from clinical trials shows SS-31 is generally well tolerated. The most commonly reported adverse events in clinical trials were injection site reactions and headache. No dose-limiting toxicities were identified in Phase 1 dose-escalation studies at doses up to 0.25 mg/kg SC. The mitochondria-targeted mechanism avoids the off-target effects of systemic antioxidants, as SS-31 does not scavenge ROS directly but instead prevents their overproduction at the source by stabilizing ETC function.